ArticleBMC geriatrics2025
The association of ultra-processed foods and risk of sarcopenia among community-dwelling older adults.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study was performed to examine the association of Ultra-Processed Foods (UPFs) intake and the risk of sarcopenia among community-dwelling older adults.
methodsA total of 368 older adults (mean age: 67.11 ± 6.21 years; 55.2% female) residing in Maragheh City, Iran, were enrolled. Body composition was estimated by a body composition analyzer and physical activity by the short-form physical activity questionnaire. UPFs intake was determined using a self-administered 147-item semi-quantitative FFQ and classified according to the NOVA system. Blood samples were also collected to evaluate relevant biochemical parameters. Raw and adjusted logistic regression models were used to examine the relationship of UPF intake tertiles (T) with risk of sarcopenia.
resultsOutcomes revealed that the overall prevalence of sarcopenia was 13.9%. In multivariable-adjusted models, higher UPFs intake (T3 vs. T1) was significantly associated with an increased risk of low muscle strength in females (OR: 2.45, 95% CI: 1.09–5.51, P = 0.030) but not in males (OR: 0.89, 95% CI: 0.36–2.20, P = 0.804) or the overall population (OR: 1.65, 95% CI: 0.93–2.92, P = 0.084). Additionally, higher UPFs intake was significantly associated with low physical performance in the overall population (OR: 1.81, 95% CI: 1.02–3.20, P = 0.041) and in males (OR: 2.82, 95% CI: 1.04–7.65, P = 0.042), but not in females (OR: 1.44, 95% CI: 0.67–3.06, P = 0.342). No significant associations were observed between UPFs intake and low muscle mass (OR: 1.81, 95% CI: 0.74–4.40, P = 0.189) or overall sarcopenia (OR: 2.15, 95% CI: 0.90–5.13, P = 0.082).
conclusionsThis study identified significant associations between higher UPF consumption and both reduced muscle strength in community-dwelling older women and impaired physical performance in older men. However, no significant associations were found between UPF intake and muscle mass or overall sarcopenia diagnosis. Further large-scale prospective studies are warranted to confirm these findings and elucidate the role of UPF intake in the development of sarcopenia in aging populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.